AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
20 5월 2024 - 10:15PM
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM” or the “Company”) today announced that
AIM Chief Executive Officer Thomas K. Equels will participate in
two upcoming investor conferences.
Details for the presentations are as
follows:
Event: Healthcare Company
Showcase hosted by Alliance Global PartnersDate and
Time: Tuesday, May 21, 2024, at 3:20 PM ETWebcast
Link
Event: LIVE! with Webull
Corporate Connect: Virtual Biotech Investment WebinarDate
and Time: Wednesday, May 22, 2024, at 3:40 PM ET
Webcast Link
Live webcasts of the presentations will be
accessible on the Events page of the Investors section of the
Company’s website, aimimmuno.com.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.
For more information, please
visit aimimmuno.com and connect with the Company
on X, LinkedIn, and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
AIM ImmunoTech (AMEX:AIM)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024